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Abstract
Background: During the set-up phase of an international study of genetic influences on outcomes from sepsis, we
aimed to characterise potential differences in ethics approval processes and outcomes in participating European
countries.
Methods: Between 2005 and 2007 of the FP6-funded international Genetics Of Sepsis and Septic Shock (GenOSept)
project, we asked national coordinators to complete a structured survey of research ethic committee (REC) approval
structures and processes in their countries, and linked these data to outcomes. Survey findings were reconfirmed or
modified in 2017.
Results: Eighteen countries participated in the study, recruiting 2257 patients from 160 ICUs. National practices
differed widely in terms of composition of RECs, procedures and duration of the ethics approval process. Eight (44.
4%) countries used a single centralised process for approval, seven (38.9%) required approval by an ethics
committee in each participating hospital, and three (16.7%) required both. Outcomes of the application process
differed widely between countries because of differences in national legislation, and differed within countries
because of interpretation of the ethics of conducting research in patients lacking capacity. The RECs in four
countries had no lay representation. The median time from submission to final decision was 1.5 (interquartile range
1–7) months; in nine (50%) approval was received within 1 month; six took over 6 months, and in one 24 months;
had all countries been able to match the most efficient approvals processes, an additional 74 months of country or
institution-level recruitment would have been available. In three countries, rejection of the application by some
local RECs resulted in loss of centres; and one country rejected the application outright.
Conclusions: The potential benefits of the single application portal offered by the European Clinical Trials
Regulation will not be realised without harmonisation of research ethics committee practices as well as national
legislation.
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Key messages
 The survey highlights the diversity in ethics
assessment and approval procedures at national and
local level across the EU for research involving
genetic material and patients lacking capacity
 The improvements introduced by the European
Clinical Trials Regulation to limit the adverse
consequences of such variation are unlikely to be
realised if current national variations in
interpretation of research ethics guidance persist
 To improve the coherence and integration of ethics
committees decision-making additional measures
may be required to ensure consistent interpretation
of national law across Europe
Background
Sepsis has been described as “one of the oldest and most
elusive syndromes in medicine” [1]. Sepsis is a condition
with high mortality risk. Many factors, such as genetics,
age, gender, ethnicity, comorbid conditions, number of
dysfunctional organs and temporal trends in markers of
acute physiological derangement have been associated
with sepsis outcomes [2–9].
The GenOSept project was conceived by the European
Critical Care Research Network of the European Society for
Intensive Care Medicine (ESICM) to investigate the poten-
tial impact of genetic variation on the host response and
outcomes in sepsis. It was part-funded in 2004 for 4 years
by the European Union 6th Framework Programme
(https://www.esicm.org/research/trials/endorsed-trials/com-
pleted-projects-supported/). The collaboration has contin-
ued since through additional specific project funding. The
aims of the project were to identify possible genetic determi-
nants of outcome from sepsis in an international cohort of
critically ill patients, and to build an intensive care medicine
genetics collaboration between clinicians and scientists
across Europe. GenOSept was launched in January 2005,
with 18 countries and 160 intensive care units (ICUs) par-
ticipating. Three genome centres (in Bonn, Paris and Ox-
ford) supported the project. A total of 2257 evaluable
patients were recruited between May 2006 and December
2008, providing important insights into the epidemiology
and genetics of sepsis in Europe [10–16]. Collaborative ana-
lytical work continues using the samples which are stored
in biobank facilities at the Wellcome Trust Centre for Hu-
man Genetics in Oxford.
European research: regulatory framework
A key component of the set-up phase of GenOSept was to
determine the approval processes and outcomes of local
and national ethics committees presented with a common
protocol for genetic analysis in critically ill patients, many
of whom would lack capacity. There are several European-
level regulations of relevance to genetics research (Table 1).
At the time GenOSept was conceived in 2004, clinical trials
performed in countries within the European Union (EU)
were required to adhere to the requirements of Good Clin-
ical Practice described in the European Clinical Trials Dir-
ective 2001/20/EC (http://ec.europa.eu/health/human-use/
clinical-trials/directive/index_en.htm), which was issued in
April 2001 and transposed into the national laws of each
EU member state by 2004. Individual institutions within
EU countries are not permitted to introduce different re-
search ethics legislation and are expected to adopt the prin-
ciples of the EU Directive, by a process of “transposition”.
Such process requires the EU member states to enforce the
directive by passing appropriate legislative implementation
measures. Individual nations within the EU may also adopt
their own national ethical guidance, which may (or may
not) be accompanied by a national review process (or a
local review process based on national guidance).
While the aims of the Directive were commendable in
terms of attempting to harmonise research processes and
safeguard persons enrolled in clinical trials, the guidance
posed certain challenges which hampered the conduct of
clinical research. The Directive failed adequately to recognise
the special circumstances of research conducted in emer-
gency care when patients may lack capacity and surrogates
can be unavailable, and made no provision for ‘observational’
research lacking direct potential benefit to the participant.
The application of the Directive was associated with in-
creased economic, bureaucratic and administrative burdens
and, especially in the case of multi-national studies, delays in
the approval process, related to the fact that each member
state’s research ethics apparatus could interpret the principles
of the Directive in different ways. Given variations in national
regulatory pathways, this resulted in research applications in-
volving patients lacking capacity being rejected in some
countries and approved in others, as we detail below.
Key ethical issues posed by the GenOSept project
within this regulatory framework include the following:
I. The lack of capacity inherent in critical illness
challenged the requirement to respect patient
autonomy in obtaining consent.
II. The possibility of obtaining informed consent from
surrogate decision-makers (‘legal representatives’) is
much more difficult in the time-limited context of
emergency care. This specific issue was mitigated
by the possibility of obtaining blood for DNA test-
ing for GenOSept at any time and patient data
could be recorded retrospectively.
III. The European Clinical Trials Directive created a
sematic confusion by referring to observational
research as ‘non-therapeutic’, in the sense that such
studies may have no direct benefit to the
participants. However, they may benefit future
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patients or populations through enhanced scientific
knowledge. The Directive did not acknowledge this
important distinction.
IV. Public concerns about the security and privacy of
genetic data [17] appeared to conflict with the
study’s methodological requirement to transfer
human genetic material across national borders for
analysis in the genotyping centres.
V. The requirement to respect confidentiality of personal
data required a study design which preserved
individual de-identification while retaining the
capacity to link genotypic with phenotypic data.
Linkage might also be necessary in the event that
a participant were retrospectively to request the
results of analyses performed on their samples.
Preserving individual de-identification, while also
retaining capability for data reconciliation where
required, poses questions around the true sense
and limitations of anonymization of data, as in-
formatics technique evolve and the potential for
Table 1 European regulations, position statements and advisory bodies affecting clinical research
Document Source Impact
Helsinki Declaration and
the Universal
Declaration on the human
genome and
human rights adopted by
UNESCO (1997)
http://www.unesco.org/new/en/
social-and-human-sciences/themes/
bioethics/human-genome-and-human-rights/
Need for legal representative
or deferred consent,
in the event of incapacity;
Genetic counselling;
Research should ‘contribute to
the health benefit of
other persons in the same age
category or with the
same genetic condition...’
International Declaration
on Human Genetic
Data (2003)
http://www.unesco.org/new/en/
social-and-human-sciences/themes/
bioethics/human-genetic-data/
Recognition of ‘special status’
for human genetic
data
The Charter of Fundamental
Rights of the
EU (2000)
http://www.europarl.europa.eu/
charter/default_en.htm
Protection of personal data
European Directive on
processing and free
movement of personal data
(Directive 95/46/EC)
http://eur-lex.europa.eu/LexUriServ/
LexUriServ.do?uri=CELEX:31995L0046:en:HTML
Protection for individuals
about the processing
and free movement of
personal data
European Group on Ethics
in Science and
New Technologies
https://ec.europa.eu/research/
ege/index.cfm
An advisory body to the
European
Commission on
ethical aspects of science and
new technologies
European Clinical Trials Directive
2001/20/EC
http://www.eortc.be/Services/Doc/
clinical-EU-directive-04-April-01.pdf
Requirement for prior
informed
consent from legal
representative made
emergency
research impossible;
Semantic confusion of
‘therapeutic’
and ‘non-therapeutic’
research
The International Conference
on Harmonisation
Guidance on Good Clinical
Practice (Topic E6)
(CPMP/ICH/135/95)
http://www.ema.europa.eu/docs/
en_GB/document_library/
Scientific_guideline/2009/
09/WC500002874.pdf
Principles of good clinical
practice
in clinical trials
research
The Good Clinical Practice
Directive 2005/28/EC
http://eur-lex.europa.eu/LexUriServ/
LexUriServ.do?uri=OJ:L:2005:091:0013:0019:en:PDF
Supplementing the Clinical
Trials Directive
European Clinical Trials
Regulation 2014
http://ec.europa.eu/health/human-use/
clinical-trials/regulation/index_en.htm
Improving coordination of the
application process for
trials involving multiple
countries,
with creation of
single EU entry
point and
trials databank
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databases to be combined, integrated and cross-
referenced increases.
To study the approaches to these issues taken by the
research ethics committees, we therefore undertook an
analysis of the processes and outcomes of ethics reviews
across the European countries participating in GenOSept.
Methods
A GenOSept project national coordinator was appointed
in each country to identify and support ICUs to consent,
recruit, and obtain a single set of blood samples from pa-
tients with severe sepsis or septic shock due to community
acquired pneumonia (CAP), peritonitis, severe pancreatitis
or meningococcal disease.
Data protection
Individual de-identification was achieved while retaining
the capability for data reconciliation, phenotypic integra-
tion and retrospective identification in the event of investi-
gator enquiry, by using three coded numerical systems for
clinical data, blood and DNA samples prior to the genomic
analysis. A “linked anonymous” (de-identified) system in-
volving a code specifying country ID (in letters e.g.UK), site
ID (numerical) and patient ID (numerical) was used. This
code was manually entered into the eCRF (electronic Case
Report Form) and attached as a bar code to the blood sam-
ples and subsequently to the extracted DNA. Only the local
clinician could link specific patients to their phenotypic
data; the genome centres could only link the blood sample/
DNA to the corresponding non-identified phenotypic data.
The link between all three could only be made by an inde-
pendent data Trustee, an academic lawyer from the UK
with expertise in European legislation appointed by the
project steering committee. It was stipulated that genetic
information would not be made available to the patient.
Ethics and consent
The protocol included information about current European
research legislation and a detailed description of the direc-
tives or position statements available at the time. The infor-
mation sheet and consent form included a description of
the project in non-medical terms which national coordina-
tors were responsible for translating into their respective
languages.
Following submission of the project to research ethics
committees (RECs) in each country, national coordina-
tors were subsequently invited to provide details of the
submission process and outcome at study set-up, and
then again following establishment of the European
Regulation. The survey aimed at evaluating the following
aspects for each participating European Country:
 organisational arrangements (whether the approval
procedure had been centralised at national level, or
whether a local or regional process had to be
followed)
 the number of intensive care units involved within
each participating nation
 the form in which the application was made
(whether via a web portal or in hard copy)
 the usual composition of the REC (detailing the
number of lay members and those with medical
or legal expertise)
 the month and year of submission for ethics
approval and the duration of the process until
approval
 whether approval was granted to all units within
each nation, some units only, or whether refused
 the need for submission of further information to
the REC
 whether national guidelines existed for the conduct
of research in critically ill patients
The survey explored both whether national ethics guid-
ance existed, and whether a national review and approval
process was in place. Data on the baseline characteristic of
the submission process and ethics approval was reported
using descriptive statistics with absolute and percentage
values, median and interquartile ranges, as applicable and
relevant to each result. Where comparisons between groups
of countries were required (with regards to the presence or
absence of a centralised approval process, and whether na-
tional guidance was available or not), inferential statistics
were conducted in the form of linear regression analyses.
Results
Results are summarised in Table 2.
Organisational setup, number of ICUs involved and
format
Eighteen countries were willing to participate, incorporat-
ing 160 ICUs. The median number of ICUs involved in
each country was 7 (interquartile range 2–12), the range
being 1–28. Eight (44.4%) countries used a single centra-
lised national or regional ethics committee for approval,
seven (38.9%) required approval by an ethics committee in
each participating hospital, and three (16.7%), Portugal,
Spain and the Czech Republic, required submission to both
a centralised and a local approval process. All countries
used a paper-based application process except the UK,
where a web-based system was in place. Results are sum-
marised in Tables 2 and 3.
Usual composition of RECs
Ethics committees included lay members in 14 (77.8%)
countries and legal expertise in 13 (72.2%). In four (22.2%)
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countries (Croatia, Greece, Hungary and Poland) the ethics
committees were exclusively composed of medical doctors,
with no patient or public (lay) representation.
Timing and duration of the approval process
Submissions for ethics approval were made, in the vari-
ous countries, between May 2005 and November 2007.
The median time from submission to final decision was
1.5 (interquartile range 1–7) months. In nine (50%)
countries the application was approved within 1 month,
while in six it took over 6 months; the duration was cal-
culated as a “combined permissions process” (the times
presented here were those including all regulatory and
ethical steps between application submission and grant-
ing of permission to proceed). In Hungary the process of
submission, initial rejection, and requests for clarifica-
tions and resubmission following appeal took more than
2 years before approval was granted, by which stage it
was no longer possible to recruit centres.
Centralisation of approval did not confer greater effi-
ciency. Median (Interquartile range) approval time in the
countries with a centralised (national and/or regional)
approval process was 1 (1–7) month, versus 2 (1–7)
months in countries without such centralisation (linear
regression analysis p = 0.57, r2 = 0.02).
If the nine countries with approval times of more than
1 month had been as efficient as those with approval
times of 1 month or less, an additional 74 months of po-
tential country or institution-wise recruitment would
have been available in the first 2 years of the project.
Approval outcomes
Ethics applications were approved for all participating
ICUs in 14 countries. In three countries (Germany, Italy
and Israel) the local ethics committees at some hospitals
rejected the application, hence the study could only
proceed in the remainder. In particular, in Italy approval
was obtained for 14 (63.6%) of the 22 ICUs willing to
participate; in Israel only for 5 (55.6%) out of 9 ICUs,
while in the case of Germany the proportion was 12
(80%) out of 15 ICUs. This clearly indicates different in-
terpretations of the same Directive within the same na-
tional regulatory environment. Portugal was unable to
participate at all because one local committee and the
national committee rejected the proposal.
Reasons for rejection of the application were diverse.
They included disagreement about the acceptability of
performing genetic research in incapacitated patients
and taking blood from an unconscious patient (Italy),
concerns about sending blood samples out of the coun-
try (Israel), and doubts about security of anonymity, val-
idity of assent from relatives or legal representative,
inclusion criteria and selection of genes to be studied,
and concerns about unauthorised use of genetic data. In
Portugal the application was rejected primarily because
of concerns about the commercial use of human tissue
and genetic data, as one of the scientific partners was
SIRS-Lab, a university spin-off company; approval could
not be obtained despite clear agreements about the use
of intellectual property and the fact that the EU encour-
aged such partnerships.
Need for submission of further information to the REC
In seven countries the applicants were required to sub-
mit additional information or modify the application. In
Austria for example, the law required informed consent
from the patient, thereby excluding patients without
capacity; for this country the protocol was therefore
modified to include only conscious patients capable of
giving informed consent.
Data access requests
No patient included in the study requested access to
their information; hence the Data Trustee’s adjudication
was not required at any time.
National guidelines
Guidance at national level on the conduct of research in
critically ill patients existed for 9 (50%) of the countries
(Austria, France, Israel, Italy, the Netherlands, Poland,
Serbia, Spain and the UK). Importantly, the fact that a
Table 3 Characteristics of the RECs across the various European
countries involved in GenOSept
Characteristic Median (IQR) or n
(%)
[Range]
No of ICUs per country 7 (2–15)
[1–28]
Countries with centralized (national/regional) REC
only
8 (44.4%)
Countries with local REC only 7 (38.9%)
Countries with both centralized and local REC 3 (16.7%)
Countries with paper application process 17 (94.4%)
Countries with online application process 1 (5.6%)
Medical members of REC 18 (100%)
Lay and Legal members of REC 13 (72.2%)
Lay but no Legal members of REC 1 (5.6%)
Approval at all units within country 14 (77.8%)
Approval at some units within country 3 (16.7%)
No approval at country 1 (5.6%)
Application process duration (months) 1.5 (1–7)
[1–24]
Additional information or modification required 7 (38.9%)
Countries with National guidelines for research in
critical care
9 (50%)
IQR inter-quartile range, n absolute number, % percentage
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country provides national guidance does not necessarily
imply that there is a centralized review process to inter-
pret such guidance. Indeed local institutions may inter-
pret national guidelines in different ways. The existence
of national guidelines was not associated with shorter
time to approval, or with greater consistency in
within-country decision making. Median (Interquartile
range) approval time in the countries with existing na-
tional guidance was 1 (1–4) month, versus 2 (1–7)
months in countries without guidance (linear regression
analysis p = 0.91, r2 = 0.001).
Discussion
We found substantial and persisting variations between
EU member states in the organisation, structures, pro-
cesses, efficiency, and decision-making of research ethics
committees (RECs) in their assessments of an EU-funded
observational study investigating the genetics of sepsis. In
three countries decisions were inconsistent between indi-
vidual centres, while one country did not allow any of its
citizens to participate. The existence of national guidance
was not always complemented by a centralized review
process with uniform interpretation of such guidance. It
seems paradoxical that, in two of the nine countries (Italy
and Israel) where national guidance for ethics approval
did exist, differential interpretation across the various local
institutions led to approval being granted only for some of
the centres willing to participate. In some centres delays
in approvals and idiosyncratic requirements for protocol
modifications hampered timely site initiation and patient
accrual. If the nine countries with approval times of more
than 1 month had been as efficient as those with approval
times of 1 month or less, an additional 74months of
country or institution- level recruitment opportunities
would have been realised in the first 2 years. Unnecessarily
lengthy and laborious research ethics approval processes
negatively impact on the perceived efficiency of the
process, leading to increased dissatisfaction amongst aca-
demics [18]. The responses from some of the RECs in-
volved in assessing the GenOSept application suggests
unwarranted and potentially paternalistic exclusion of pa-
tients lacking capacity [19], the consequence being that
critically ill patients may be excluded from benefiting from
research participation.
The lack of standardized membership requirements
for RECs which we have identified, and the recognised
lack of a common ethics training curriculum, could also
contribute to variation in practices and outcomes [20].
It is possible that RECs identified unique difficulties
relating to cross-border genetics research which may
have contributed to diversity in decision making. How-
ever, every REC received the same protocol for evalu-
ation, and the critical care patients recruited to the
various centres all met the same inclusion and exclusion
criteria across the various EU countries. We therefore
must conclude that the diversity in REC outcomes was at-
tributable to non-clinical factors at an institutional, or na-
tional, level. Some of these factors must have been related
to country-specific attitudes or legislation. Such diversity
of decision-making between RECs is inconsistent with the
principle of a harmonised approach to ethics across na-
tional borders. It is likely that attitudes amongst ethics
committee members to genetics research in patients lack-
ing capacity may have become modified in the years since
the Human Genome project was completed.
Attempts to standardise the ethics of clinical research
over many years [21, 22] have been hampered by the
failure of the European Clinical Trials Directive 2001
[23] to accommodate the particular challenges of re-
search in emergency settings [23–29], by widely differing
interpretations of ethical principles by national or local
RECs, as well as variations in approval processes [21–
26]. The absence of harmonised processes and standar-
dised interpretation delays studies, creates additional
costs, and may prevent citizens from participating in re-
search, while failing to provide added protection for par-
ticipants [30–35].
The European Clinical Trials Regulation (http://ec.
europa.eu/health/human-use/clinical-trials/regulation/
index_en.htm) is a welcome attempt to resolve these
difficulties (anticipated implementation in 2019). It re-
quires that research applications are processed by one
member state with the outcomes applying to all. This
measure resembles the approach of the US National
Institutes of Health, which have recently mandated
the use of a single Institutional review board for
multi-centre clinical studies. However, while the
Regulation requires member states to cooperate in
assessing a request for authorisation of a clinical trial,
it does not include cooperation on matters ‘of an in-
trinsically national nature, such as informed consent’(-
paragraph 6), though it does state that ‘ethics
committees… should ensure the involvement of layper-
sons, in particular patients or patients’ organisations’.
It remains to be seen whether the requirement to
process approvals through a single member state will
solve the issue of wide variation in national research
ethics processes and outcomes. It is evident that the
current trials regulations, combined with the absence
of standardised proceedures and training of RECs
have increased the complexity and burdens of re-
search governance, and have reduced the opportunity
for participation in research, without evidence of
benefit to participating subjects [36].
Additional issues and challenges
An example of additional challenges faced by researchers
in this area is provided by the UK. Here the Mental
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Capacity Act (2005) makes welcome provision for ‘non-in-
terventional’ and emergency research; however, in the
event of a consented person losing capacity during the re-
search study, ‘advice’ must be obtained from the next of
kin or equivalent consultee on whether the incapacitated
person would have wished to continue with the study,
even if the intervention has already occurred and that spe-
cific individual is now in the follow up phase [37]. If the
consultee is of the view that the patient would not have
wished to continue in the study, the patient must be with-
drawn and the data destroyed or de-identified, unless the
patient specifically consented to continue in the study in
the event of loss of capacity.
A further example is the case of patients consenting to
participate provided there was no risk that an organisa-
tion related to the government could access their data.
In such a situation, medical, nursing and research staff
would be allowed to use the data for the purposes of the
study, but a government regulatory authority would not
be allowed to review the notes or the data, even in the
context of an inspection.
Strengths and limitations
The GenOSept project began data collection over 10
years ago, and our survey demonstrates the challenges
which continue to be faced by international re-
searchers across member states involving genetic ma-
terial and patients who lack capacity. Our findings
show that efficient trans-European approval processes
are possible. However, unexplained variation between
some local and national ethics committees is having
an undesirable effect on patient participation. While
our survey did not allow for interaction with individ-
ual ethics committees to explore in greater detail the
reasons for these variations in decision-making, we
were able to use the information provided in the ap-
proval or rejection letters.
Conclusions
Our study highlights the diversity and adverse conse-
quences of variation in ethics assessment and approval
procedures at national and local level across the EU for
research involving genetic material and patients lacking
capacity. The improvements introduced by the Euro-
pean Clinical Trials Regulation will not be realised if
current national variations in interpretation of research
ethics guidance persist. The invaluable service provided
by these committees to patients and the research com-
munity may require targeted support to develop a com-
mon interpretation of European legislation and the
moral assumptions underpinning research in critically
ill patients lacking capacity.
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